Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C).

ABSTRACT:

Objective

The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE.

Design

We used nested case-control study design.

Setting

This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repositor

SUBMITTER: Kravchenko OV 

PROVIDER: S-EPMC9806069 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature